The sharp decline in operating margin from 34.1% in 2024Q1 to 1.9% in 2026Q2 suggests that the AZSTARYS acquisition and expanded salesforce have yet to generate operating leverage. The gross margin erosion to 55.2% may indicate a higher mix of lower-margin products or increased royalty obligations, which could persist if the ADHD portfolio grows faster than the opioid franchise. Investors should monitor whether the 41% ADHD revenue growth can eventually absorb the elevated cost base, as the current margin trajectory appears unsustainable without further scale.

The decline in ROIC from 5.9% to 0.3% over ten quarters indicates that the company is not yet earning returns above its cost of capital on recent investments. The flat equity base near $312M despite rising debt suggests that the acquisition was largely debt-funded, which amplifies the drag on ROE when earnings are depressed. If the ADHD portfolio does not deliver the expected synergies, the goodwill and intangibles recorded may face impairment risk, further eroding returns.

The 35-day increase in the cash conversion cycle suggests that Collegium is taking longer to collect receivables while paying suppliers more quickly, which may strain liquidity. The DSO of 117 days is notably high for a specialty pharma company, possibly reflecting payer mix or rebate accrual timing. The sharp drop in DPO to 8 days from 13 days in 2024Q1 could indicate a shift in payment terms or a deliberate strategy to maintain supplier relationships, but it reduces the company's ability to finance operations with trade credit.

The combination of rising debt and falling operating income has pushed interest coverage to a precarious 0.31, meaning operating income covers less than one-third of interest expense. This suggests that the company may need to rely on cash reserves or refinancing to meet debt obligations, especially if the current margin pressure persists. The D/EBITDA ratio of 12.53 in 2026Q2 is elevated relative to the 6.75 in 2024Q2, indicating a significant increase in leverage that could constrain future borrowing capacity.

The near-unity current ratio suggests that Collegium's current assets barely cover its current liabilities, which could be problematic if revenue collections slow or if unexpected cash outflows arise. The quick ratio of 0.84 indicates that even after excluding inventory, the company may struggle to meet immediate obligations without relying on inventory liquidation. Given the high DSO of 117 days, the liquidity position appears vulnerable to any disruption in receivables collection, though the strong operating cash flow of $71.3M in 2026Q2 provides some offset.